Depomed Executes an Exit Strategy for Its Opioid Drug

Depomed Executes an Exit Strategy for Its Opioid Drug
After reporting that Collegium Pharmaceutical (NASDAQ: COLL) will take over commercializing its top-selling drug, Nucynta, Depomed Inc. (NASDAQ: DEPO) shares rallied 10% yesterday. The pact is good news for the company because its revenue and profit have been falling this year due to waning demand for Nucynta. Does this deal make Depomed a buy? Exit, stage left Depomed probably wishes it had... Read More

Middle East Shares Mostly Drop In Line with World Stocks, Amid Geopolitical Worries

Middle East Shares Mostly Drop In Line with World Stocks, Amid Geopolitical Worries
Middle East shares mostly fell in line with world stocks and amid geopolitical jitters. Earlier in the week, Qatari stocks rose on hopes tensions would ease between Qatar and some of its neighboring countries. However, Saudi Arabia, the United Arab Emirates and Bahrain, in an apparent snub of Qatar, did not send their heads of state to this week’s regional... Read More

Forget Amazon and Alphabet: Here's Why Apple Will Become the First $1 Trillion Company

Forget Amazon and Alphabet: Here's Why Apple Will Become the First $1 Trillion Company
The battle for the first trillion-dollar company is slowly nearing its conclusion. Currently, Apple (NASDAQ: AAPL) , sitting with an $875 billion valuation, appears increasingly likely to claim the title of the first trillion-dollar company. Yet while it now may seem like a fait accompli, the race to be first to a trillion-dollar market cap wasn’t always promised for Apple.... Read More

Veeva Systems (VEEV): Trade the Reaction to Earnings, Not the Report

Veeva Systems (VEEV): Trade the Reaction to Earnings, Not the Report
Yesterday, Veeva Systems (VEEV) released third quarter results. They reported a small beat of expectations in terms of EPS and issued guidance that was roughly in line. The market initially responded positively with the stock hitting a high of $61.47, but then reversed and dropped all the way to $54 as the post-earnings conference call with analysts revealed questions about... Read More

The 2 Likely Reasons Novavax Inc. Rocketed Higher by 25% in November

The 2 Likely Reasons Novavax Inc. Rocketed Higher by 25% in November
What happened Shares of Novavax (NASDAQ: NVAX) , a clinical-stage small-cap biotech company focused on the development of recombinant nanoparticle vaccines, surged by 25% during the month of November, according to data from S&P Global Market Intelligence . The reasoning for the move appears to be traceable to two catalysts. So what Firstly, Novavax wound up reporting its fiscal third-quarter... Read More